


PHARMACEUTICAL 2017

CorMedix Inc. Rank 174 of 292







PHARMACEUTICAL 2017

CorMedix Inc. Rank 174 of 292



The relative strengths and weaknesses of CorMedix Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of CorMedix Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 94% points. The greatest weakness of CorMedix Inc. is the variable Net Income, reducing the Economic Capital Ratio by 96% points.

The company's Economic Capital Ratio, given in the ranking table, is 46%, being 43% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	21,832
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,092
Liabilities, Non-Current	0
Other Assets	5.0
Other Compr. Net Income	19
Other Expenses	-117
Other Liabilities	0
Other Net Income	-143
Other Revenues	0
Property and Equipment	70
Research and Development	15,735
Selling, General and Administrative Expense	8,883

Output Variable	Value in 1000 USD
Assets	21,906
Liabilities	4,092
Expenses	24,501
Revenues	0
Stockholders Equity	17,815
Net Income	-24,644
Comprehensive Net Income	-24,634
Economic Capital Ratio	46%

